Introduction
High dose chemotherapy (HDCT) followed by autologous stem cell transplantation in chemorefractory Hodgkin lymphoma (HL) patients resulted in a disappointing long-term progression-free survival (PFS) lower than 30-40% [1] [2] [3] .
Different strategies have been developed: target therapies and risk adapted intensification of salvage treatment. Brentuximab vedotin was associated with an overall response rate >80% [4] and a 5-year overall survival (OS) and PFS of 41 and 22%, respectively [5] . Morschhauser et al. [6] utilized an intensified treatment comprising tandem autologous transplant for high-risk patients according to the SFGM score, showing a 5-year PFS and OS of 46 and 57%.
A sequential program was previously shown to be feasible and effective for resistant HL with a 2-year event free survival (EFS) of approximately 50% [7] . We have found that high dose melphalan followed by autologous stem cell transplant (ASCT) represents an effective bridge to second transplant, either autologous or allogeneic [8] , with 77% of refractory patients reverted to complete (CR) or partial remission (PR) by melphalan conditioning. Furthermore, we found that unmanipulated haploidentical transplant (Haplo-SCT) with high dose post-transplant cyclophosphamide (PT-Cy) was a potential effective strategy with a 3-year PFS and OS of 63 and 77%, respectively [9] .
We conducted a retrospective analysis to explore the feasibility and efficacy of a sequential autologous-haploidentical transplant approach (tandem auto-haplo transplant) for patients with poor prognosis HL.
Patients and methods
From September 2008, 26 consecutive refractory HL were included in a tandem auto-haplo transplant program at Humanitas Cancer Center (Rozzano, Italy) and Institut Paoli Calmettes (Marseille, France). Every patient provided informed consent. Nineteen patients were included in previous manuscripts [8] [9] [10] . Inclusion criteria were: lack of HLA-matched related or unrelated donor; primary refractory or relapsed HL refractory to conventional second-line salvage chemotherapy. Exclusion criteria comprised: (1) previous HDCT followed by ASCT or previous allogeneic SCT; (2) progressive disease after autologous transplant requiring further treatment; (3) active uncontrolled infections, CNS disease, Karnofsky performance status <60 or severe organ dysfunction, including a left ventricular ejection fraction <40%, DLCO <50% or creatinine clearance <50 ml/min.
Salvage chemotherapy regimens are summarized in Supplementary Methods.
HDCT consisted of high-dose melphalan (200 mg/m 2 ) [8] . Two different conditioning regimens prior to Haplo-SCT with PT-Cy were employed: (1) a non-myeloablative (NMA) regimen comprising Cy 14.5 mg/kg on days −5 and −6, fludarabine 30 mg/m 2 from day −6 to day −2 and lowdose TBI (2 Gy) on day −1; (2) a reduced intensity (RIC) regimen comprising thiotepa 10 mg/kg on day −6, cyclophosphamide 30-60 mg/kg on day −5, fludarabine 30 mg/ m 2 on day −5 to day −2, d low-dose TBI (2 Gy) on day −1. HLA typing, bone marrow (BM) or peripheral blood stem cells (PBSC) harvest, graft-versus-host-disease (GVHD) prophylaxis, supportive care and statistical analysis are summarized in Supplementary Methods.
Results
Patient characteristics are summarized in Supplementary  Table 1 . Notably, 70% of the patients had active disease with a positive PET scan at the time of autologous transplant (44% progressive disease [PD], 15% stable disease [SD], 11% PR) and 23 out of 26 (88%) fell into the highrisk group according to the SFGM prognostic index [6] . After HDCT 11 patients obtained a CR, resulting in 73% CR rate before haploidentical transplantation. Median time between ASCT and haploidentical HSCT was 64 days (range 41-149 days). Twenty-five (96%) patients were evaluable for ANC engraftment, only one patient suffered from primary DSA-linked graft failure. The median time to achieve unsupported ANC and platelet counts was 21 days (range [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] (Fig. 1a  and b) . Cause of death was represented by disease progression in 4, infections in 4 and myelodysplastic syndrome in 2 subjects. 3-year CI of relapse was 28% (95% CI, 11-49), resulting in a 3-year PFS rate of 55% (95% CI, 32-73) (Fig. 1c and d) . Median time from ASCT to relapse was 254 days (range 130-633). The 2-year CI of grade 2-4 aGVHD and moderate-severe cGVHD was 23% (95% CI 9-40) and 4% (95% CI 0-17), respectively ( Fig. 1e and f) . All aGVHD cases were of grade 2. Only one patient had cGVHD of severe degree without experiencing previous EBV reactivation.
Univariate analysis of the main factors affecting disease outcome is summarized in Table 1 . Disease status and PET scan status before HDCT represented the main variables dictating outcome in terms of CI of relapse and PFS. No patients in CR before HDCT relapsed after haploidentical transplant compared with 8 subjects with active disease before HDCT (0 versus 44%, P = 0.01). Consistently, 3-year PFS was 86 and 80% for patients in CR/PR or with a negative PET scan before ASCT vs. 37 and 45% of patients with SD/PD or a positive PET scan, respectively (P = 0.01 and P = 0.09). Patients receiving peripheral blood stem cells (PBSC) for haploidentical transplant had a tendency for reduced relapsed incidence relative to those receiving bone marrow (BM) stem cells (P = 0.09). In accordance, on multivariate analysis (data not shown), active disease status (SD/PD vs. CR/PR) before ASCT was an independent predictive factor for adverse 3-year OS (HR: 11.4, 95% CI 1,2-100, P = 0.02). Moreover, on multivariate analysis also HCT-CI ≥ 3 was negatively associated with 3-year OS (HR 9.9, 95% CI 1,8-54.8, P = 0.008). Of note, graft type (PBSC vs. BM) was not independently associated with a worse outcome.
Discussion
The present analysis not only confirms the efficacy and safety of a sequential transplant strategy comprising HDCT followed by allogeneic transplantation for patients with refractory HL [7, 11, 12] , but extends the finding to T-cellreplete Haplo-SCT with PT-CY. Our results showed that haplo-SCT is a feasible procedure and the NRM was 16%, mainly due to infectious complications. Acute GVHD was only of grade 2 in 23% of the patients and cGVHD occurred only in 4% of the cases.
Taking into account the poor prognostic features of our patients, comprising 88% within the SFGM high risk group and 70% with active disease before ASCT, 61% 3-year OS and 55% 3-year PFS compared well with previous experiences [13, 14] . We confirmed that high dose melphalan was an effective strategy able to revert chemorefractory disease into CR in 11 cases, thus enabling patients to receive further therapy. We described that pre-HDCT disease status (CR/ PR vs. SD/PD) was the main independent variable affecting disease outcome in terms of PFS (HR: 11.4, P = 0.02). Of note, we were not able to recognize a different outcome according to SFGM prognostic index and PET status before transplant: this may be due to the limited patients number rather than the efficacy of the tandem procedure. The fact that both patients in CR and PR before HDCT may benefit from a tandem-haplo transplant program suggests that PR status should not preclude the possibility of cure if HDCT is followed by allogeneic transplant. Our transplant plan partially reverted the dismal outcome of patients with chemorefractory HL, partially because of persistency of active disease after HDCT in 7/25 patients. These observations suggest that new experimental clinical trials employing new drugs, such as brentuximab vedotin [4, 5] (of note 6 of our patients were treated with brentuxiamb vedotin before ASCT and 3 achieved CR) or immune check point inhibitors [15] , should be offered to patients still with active disease after HDCT in order to improve disease status before allogeneic SCT.
We also found that high HCT-CI ≥ 3 before HDCT is a negative independent predictor for adverse OS in a tandem autologous-haploidentical strategy. This effect on OS was found in other series concerning haplo-SCT [16] , but not in a recent report from the Baltimore group [17] .
Although this is a small retrospective and probably biased study considering that 19 patients were already considered in previous analyses which were already published, our results also add to the open debate concerning the best strategy for refractory HL. In a recent guideline on relapsed and refractory HL, double HDCT was recommended for the high-risk group and tandem HDCTallogeneic HSCT only for selected patients [18] . Here we show that mainly chemosensitive disease achieves longterm PFS after allogeneic transplant and that patients lacking a HLA identical donor should not be excluded from a chance of cure. Indeed, unmanipulated haploidentical HSCT with PT-Cy had a very low toxicity in our group of highly pre-treated patients (>50% with a HCT-CI ≥ 3). The results of our study are consistent with recent publication showing similar profiles of toxicity between haploidentical transplant and HLA identical (MRD) or matched unrelated donor transplants [17] .
In conclusion, haploidentical-HSCT with PT-Cy looks highly effective against refractory HL, and in patients without a HLA donor should be considered a good opportunity. New strategies need to be employed in patients with active disease before haploidentical transplant in order to enhance disease outcome.
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